Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14283/jpad.2015.52 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying and Understanding Seizure Liability in Drug Development.
Int J Toxicol
January 2025
Allucent, Cary, NC, USA.
Seizures are complex electrophysiological disturbances affecting one or more populations of brain neurons. Seizures following test article (TA) exposure pose significant challenges in drug development. This paper considers the diverse neurological manifestations, mechanisms, and functional and structural assessments needed to investigate TA-related seizure liabilities, with a particular focus on nonclinical species.
View Article and Find Full Text PDFFree Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.
J Prev Alzheimers Dis
November 2024
Andrew Aschenbrenner, PhD, 4488 Forest Park Ave, STE 301, St. Louis, MO, 63108, 314-273-1041.
Article Synopsis
- A decline in episodic memory is an early sign of Alzheimer’s disease and is important in evaluating treatment effectiveness in clinical trials, particularly through various memory tests.
- This study aimed to assess the correlation between different episodic memory tests and plasma biomarkers related to Alzheimer’s, examining data from 161 cognitively normal older adults.
- Results indicated that the Free and Cued Selective Reminding Test with Immediate Recall was more sensitive to changes in cognitive function linked to certain plasma biomarkers compared to other tests, highlighting the importance of using specific memory assessments in Alzheimer’s research.
Emerging research suggests that Parkinson's disease (PD) and dementia with Lewy bodies (DLB) share underlying pathology and may represent a single, biologically defined disease spectrum. Cognitive changes are among the most worrisome symptoms for patients with PD, and are the core feature of DLB. While the cognitive changes experienced by individuals with PD and mild cognitive impairment share some clinical characteristics with patients who have undiagnosed or prodromal DLB, these changes are distinct from other types of dementias, such as Alzheimer's disease.
View Article and Find Full Text PDFApproaches to Early Parkinson's Disease Subtyping.
J Parkinsons Dis
October 2024
Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus, Denmark.
Parkinson's disease (PD) unfolds with pathological processes and neurodegeneration well before the emergence of noticeable motor symptoms, providing a window for early identification. The extended prodromal phase allows the use of risk stratification measures and prodromal markers to pinpoint individuals likely to develop PD. Importantly, a growing body of evidence emphasizes the heterogeneity within prodromal and clinically diagnosed PD.
View Article and Find Full Text PDFA phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias.
Medicine (Baltimore)
July 2024
The Regenesis Project, Santa Monica, CA.
Background: Alzheimer's disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!